Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review

Ru Yan, Shbin Jiang, Yan Wu, Xing-Hua Gao, Hong-Duo Chen

ABSTRACT

Topical calcipotriol/betamethasone dipropionate ointment/gel has been commonly used for the treatment of psoriasis vulgaris. However, the efficacy of this combination needs to be consolidated. We aimed to assess the effects and safety profile of calcipotriol/betamethasone dipropionate for the treatment of psoriasis vulgaris, using evidence based approach. Randomized controlled trials on the treatment of psoriasis vulgaris with calcipotriol/betamethasone dipropionate were identified by searching PubMed, China National Knowledge Infrastructure and the Cochrane Library. The primary outcome measure was the Psoriasis Area and Severity Index (PASI) score. Ten randomized controlled trials involving 6590 participants were included. The methodologies of the studies were generally of moderate to high quality. These trials used topical calcipotriol/betamethasone dipropionate for 4 or 8 weeks, and were compared with topical calcipotriol or betamethasone. The results showed that calcipotriol/betamethasone dipropionate was more effective than controls. A four-week treatment with calcipotriol/betamethasone dipropionate did not show any significant difference between the once-daily or twice-daily regimen. The adverse events of calcipotriol/betamethasone dipropionate were tolerable and acceptable. The reports included in this review are heterogenous and have limitations. Topical application of calcipotriol/betamethasone dipropionate once daily is an efficacious treatment for psoriasis vulgaris and is associated with few side effects.

Key words: Betamethasone, calcipotriol, psoriasis, randomized controlled trial

INTRODUCTION

Psoriasis is a common, chronic inflammatory cutaneous disease that affects 1–3% of the world population.[1] The pathogenesis is multifactorial and there are various triggering factors. It may lead to a low quality of life and reduces physical and mental functioning.[2] Psoriasis vulgaris is the most common form of psoriasis. Mild to moderate psoriasis vulgaris is usually treated topically with agents that may include vitamin D derivatives and corticosteroids.[3]

Calcipotriol and betamethasone dipropionate have been used as topical therapies in psoriasis vulgaris for many years.[4,5] Treatments are often used in combination to improve symptom control and tolerability. It was postulated that a combination of topical calcipotriol and corticosteroid may have an additive or synergistic treatment effect due to their different mechanisms of action. This is expected to be more efficacious and better tolerated than monotherapy with either drug.[6] However, calcipotriol and corticosteroids are usually not compatible because of their different pH requirements.

A compound with calcipotriol (50 ug/g) and betamethasone (0.5 mg/g) was introduced and

Access this article online

Quick Response Code: Website: www.ijdvl.com
DOI: 10.4103/0378-6323.175919

How to cite this article: Yan R, Jiang S, Wu Y, Gao XH, Chen HD. Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review. Indian J Dermatol Venereol Leprol 2016;82:135-44.

Received: June, 2015. Accepted: October, 2015.
recommended for mild-to-moderate psoriasis in 2001.[8] This formulation, available as both an ointment and a gel, combined the action of vitamin D3 analogues on keratinocyte differentiation with the anti-inflammatory effect of steroids. This reduced the side effect profile that was seen with single topical agents.[9,10] A study in a human disease model showed that the ointment and gel formulations had comparable anti-psoriatic effects.[10,11] Previous studies have used this compound, either alone or combined with other therapies, for the treatment of mild-to-moderate psoriasis.[9,12-20] The primary aim of our systematic review was to examine the efficacy and tolerability of calcipotriol/betamethasone dipropionate in the treatment of psoriasis.

MATERIALS AND METHODS

Eligibility criteria
We searched for studies regardless of the language or publication status, that met all of the following criteria: (i) randomized controlled trials involving psoriasis vulgaris patients; (ii) undergoing calcipotriol/betamethasone dipropionate ointment/gel therapy in the treatment group, without any other simultaneous treatment; (iii) undergoing calcipotriol or betamethasone ointment/gel therapy in the control group, without any other simultaneous treatment; (iv) psoriasis on the body, with or without scalp lesions.

Search strategy
PubMed, China National Knowledge Infrastructure and Cochrane library were independently searched by two investigators using the open search strings “calcipotriol,” “betamethasone,” “psoriasis”, “random,” “randomized control trial” and “randomized controlled trial.” All studies that matched the search criteria were included until April 2015. The reference lists of prior reviews, systematic reviews and trials were also checked.

Study selection and data extraction
Two investigators independently screened all studies for inclusion into the review. Eligible studies were determined and retrieved. Disagreements were resolved by consensus. They independently extracted the data from included studies with the help of standardized forms. A third investigator was assigned the checking process. The study data included the country/region of participants, interventions, number of participants with age and gender distribution, the affected sites, baseline score, mean duration of disease, duration of treatment, evaluation time, efficacy and safety.

Quality assessment
The criteria recommended by the Cochrane Collaboration Handbook were used to assess the methodological quality of included trials. It focused on the description of randomization (sequence generation progress), allocation concealment, blinding, addressing of incomplete outcome data, reporting of selective outcome and other potential threats to validity.[21] The judgment for each entry was based on the answer of a question with “Yes” indicating “low risk of bias,” “No” indicating “high risk of bias” and “unclear” indicating “either lack of information or uncertainty on the potential for bias.” Disagreements were resolved by group consensus.

Outcome measures
The primary outcomes were the percentage reduction of the PASI score, the PASI score, and the proportion of patients who achieved PASI 75 score. The secondary outcomes included the proportion of “marked improvement or clearance” by investigator assessment and occurrence of any adverse events.

Data analysis and statistical methods
The statistical analyses were performed by both investigators using the duplicate data entry facility of Revman 5.0. In addition to 95% confidence intervals, mean differences were used for continuous outcomes. The I² statistic was calculated to determine the proportion of between-study variation due to heterogeneity. The value ranges from 0% to 100% and high values indicate strong heterogeneity. If the heterogeneity was low (P > 0.1, I² < 50%), a fixed-effect model was used for analysis, otherwise a random-effect model or describe analysis was used.

RESULTS

Eligible studies
Altogether, 391 papers were identified by a systematic literature search. After screening the titles and abstracts, 378 non-relevant papers were excluded. The full text of the 13 remaining papers was retrieved. After review, 10 randomized controlled trials were finally included.[9,12-20] The study selection procedure is illustrated in a flowchart [Figure 1].
Yan, et al. Calcipotriol/betamethasone compound for psoriasis: A systematic review

Risk of bias assessment and study characteristics

All studies reported random allocation of study participants, eight of them adequately described the randomization method.[9,12-14,16,17,19,20] Six trials adequately mentioned the allocation concealment.[9,12-14,17,19] Five trials performed blinding of participants and researchers and three trials mentioned blinding of outcome assessment.[12-14,17,19,20] Nine trials addressed incomplete outcome data. All the ten trials addressed selective outcome reporting [Figures 2 and 3].[9,12-19]

Ten randomized controlled trials involving 6590 participants with psoriasis vulgaris were included in this systematic review. Five studies focused on Europeans and North Americans, two studies focused on Asians and the other three studies did not describe the origin.[9,12-20] The mean age of patients was between 40–50 years. Men were relatively more affected than women. The duration of disease was more than ten years in most of the studies. The duration of treatment ranged from four to eight weeks. The characteristics of the included studies are depicted in Table 1.

Efficacy evaluation

Comparison of calcipotriol/betamethasone dipropionate with calcipotriol [Table 2]

We identified ten trials for this comparison, involving a total of 4628 participants.[9,12-20] The frequency of application was once daily calcipotriol/betamethasone versus once daily calcipotriol in three studies, once daily calcipotriol/betamethasone dipropionate versus twice daily calcipotriol in five studies, and twice daily calcipotriol/betamethasone dipropionate versus twice daily calcipotriol in two studies.[9,12-20]

The treatment duration was 4 weeks in seven studies.[9,12,14,16,18,20] Six studies evaluated the percentage reduction of PASI score at the first week and fourth week. They showed a higher reduction in the calcipotriol/betamethasone dipropionate group (about 40% at week 1, and about 70% at week 4) compared to those in the calcipotriol group ($P < 0.001$).[12,14-16,18,20] Two of those studies conducted a meta-analysis and showed that calcipotriol/betamethasone dipropionate was more effective than calcipotriol at all evaluation time-points (Week 1: mean difference = 8.29, 95% [4.78–11.80], $P < 0.001$; Week 2: mean difference = 10.85, 95% [6.98–14.73], $P < 0.001$; Week 4: mean difference = 10.20, 95% [6.25–14.14], $P < 0.001$).[15,18]

One study also demonstrated that the PASI 75 score was observed in over 70% (111/152) of patients with calcipotriol/betamethasone dipropionate therapy in contrast to only about 40% (72/149) of patients with calcipotriol treatment ($P < 0.01$) at week 4.[15] Another study calculated the PASI scores and showed lower values...
in the calcipotriol/betamethasone dipropionate group (3.81 ± 3.27 at week 2, 2.5 ± 2.5 at week 4) than those in the calcipotriol group (5.47 ± 3.47 at week 2, 4.07 ± 3.33 at week 4) \( (P < 0.001) \). Four studies evaluated the proportion of “marked improvement or clearance” by the investigators assessment at week 4. All those studies showed a higher proportion of improvement in the calcipotriol/betamethasone dipropionate group (once daily being nearly 60%, and twice daily being around 70%) compared to those in the calcipotriol group \( (P < 0.001 \text{ or } P = 0.033) \).

The treatment duration was eight weeks in three studies. All the studies evaluated the percentage reduction of PASI score at week 4 and week 8 and showed a higher reduction in calcipotriol betamethasone dipropionate group (about 50% at week 4 and over 55% at week 8) than those in the calcipotriol group \( (P < 0.001) \). Two studies also demonstrated a PASI 75 score in about 20% patients at week 4 and in 40% patients at week 8 treated with calcipotriol/betamethasone dipropionate therapy. This was in contrast to a PASI 75 score seen in only about 6% patients at week 4 and 20% patients at week 8 treated with calcipotriol (Week 4, \( P < 0.001 \); Week 8, \( P < 0.05 \)). These studies also evaluated the proportion of “marked improvement or clearance”

![Figure 3: The judgments about each risk of bias item, presented as percentages across all included studies](image)

**Table 1: Characteristics of included studies**

| Source          | Country or region                        | Interventions of drug | Number of participants | Mean age (years) | Percentage of males affected | Mean duration of disease (year) | Affected area of body (%) | Mean PASI score | Treatment period (weeks) |
|-----------------|------------------------------------------|-----------------------|------------------------|-----------------|-----------------------------|------------------------------|--------------------------|-------------------|--------------------------|
| Mellyanawati    | Chongqing city in China                  | CBD (QD) Ointment     | 30                     | 18-70           | -                           | <30                          | -                        | -                 | 4                       |
|                 |                                          | CA (BID)              | 30                     |                 |                             |                              |                          |                   |                          |
| Menter          | 59 centers in the United States          | CBD (QD) Gel         | 482                    | 48.7±13.4       | 58.9                        | ≥10                          | 7.9±3.4                  | 8                 |                          |
|                 |                                          | BE (QD)               | 479                    | 48.5±13.8       | 59.7                        | 15.8±12.5                    | 7.8±3.7                  |                   |                          |
|                 |                                          | CA (QD)               | 96                     | 48.0±13.7       | 62.5                        | 15.9±13.3                    | 8.5±3.5                  |                   |                          |
| Fleming         | 19 centers in four European countries and in Canada | CBD (QD) Gel | 126                    | 50.1±14.9       | 57.4                        | 18.5±13.8                    | -                        | 7.7±4.6           | 8                       |
|                 |                                          | BE (QD)               | 68                     | 51.4±14.5       | 57.8                        | 18.8±14                      | 7.8±4.4                  |                   |                          |
|                 |                                          | CA (QD)               | 67                     | 52.6±15.2       | 60.8                        | 19.5±14.8                    | 7.9±3.9                  |                   |                          |
| Huang           | 2 cities (Shanghai, Beijing) in China    | CBD (QD) Ointment     | 160                    | 18-65           | -                           | <30                          | -                        | -                 | 4                       |
|                 |                                          | CA (BID)              | 160                    |                 |                             |                              |                          |                   |                          |
| Saraceno        | 9 countries                              | CBD (QD) Ointment     | 75                     | 49.1±15.9       | 45.8                        | ≥20                          | 9.49±5.39                | 4                 |                          |
|                 |                                          | CA (BID)              | 75                     | 46.3±17.0       | 54.2                        | 15.7±14.2                    | ≥20                      | 9.11±4.09         |                          |
| Kragballe       | 8 countries in Europe and Canada         | CBD (QD) Ointment     | 322                    | 47.8            | 62.4                        | 18.3                         | -                        | 10.3              | 8                       |
|                 |                                          | CA (BID)              | 327                    | 47.5            | 65.1                        | 18.3                         | -                        |                   |                          |
| Papp            | 11 European countries and Canada involving 75 centers | CBD (BID) Ointment     | 301                    | 47.5            | 57.0                        | 19.2                         | ≥10                      | -                 | 4                       |
|                 |                                          | CA (BID)              | 308                    | 46.3            | 59.2                        | 18.1                         | -                        |                   |                          |
|                 |                                          | BE (BID)              | 312                    | 47.2            | 58.5                        | 18.9                         | -                        |                   |                          |
| Douglas         | 10 countries                             | CBD (BID) Ointment     | 372                    | 47.6            | 58.1                        | 19                            | -                        | 10.8              | 4                       |
|                 |                                          | CA (BID)              | 369                    | 47.6            | 60.4                        | 18.6                         | -                        | 10.9              |                          |
|                 |                                          | BE (BID)              | 365                    | 46             | 60.8                        | 17.7                         | -                        | 10.5              |                          |
| Guenther        | 7 European countries and Canada          | CBD (QD) Ointment     | 152                    | 47.9            | 59.2                        | 18.3                         | ≥10                      | 9.9               | 4                       |
|                 |                                          | CA (BID)              | 231                    | 49             | 61.9                        | 18.5                         | -                        | 10.8              |                          |
|                 |                                          | CBD (BID)             | 237                    | 49.3            | 69.6                        | 18.3                         | -                        | 10.6              |                          |
| Kaufmann        | 106 centers in 8 countries               | CBD (QD) Ointment     | 490                    | 47.6            | 62.9                        | 18.3                         | ≥10                      | 9.9               | 4                       |
|                 |                                          | CA (QD)               | 480                    | 48.9            | 59.0                        | 20.3                         | -                        | 10.4              |                          |
|                 |                                          | BE (QD)               | 476                    | 48.2            | 61.1                        | 19.4                         | -                        | 9.8               |                          |

CBD: Calcipotriol/betamethasone dipropionate, CA: Calcipotriol, BE: Betamethasone, QD: Once daily, BID: Twice daily, PASI: Psoriasis Area and Severity Index
Yan, et al.  Calcipotriol/betamethasone compound for psoriasis: A systematic review

Table 2: The protocols and efficacy of treatment group and control group

| Source | Treatment period (week) | Treatment group | Control group | Evaluation time of outcome measurement | Efficacy (T vs. C) |
|--------|-------------------------|-----------------|---------------|----------------------------------------|------------------|
|        | Treatment       | Protocol | Number of patients | Protocol | Number of patients |                                           |
|        | group            |         |                  | group     |                  |                                           |
|        | period (week)    |         |                  |           |                  |                                           |
| CBD versus CA |
| CBD (QD) versus CA (QD) |
| Menter 2013 | 0-8 CBD (QD) | 482 | CA (QD) | 96 | 1b (week 4, week 8) | 1a (week 4): 46.4% versus 32.2% (P<0.001) |
| | | | | | 3 (week 4, week 8) | 1b (week 8): 55.8% versus 43.6% (P<0.001) |
| | | | | | 4 (week 4, week 8) | 3 (week 8): 21.3% versus 5.9% (P<0.001) |
| Fleming 2010 | 0-8 CBD (QD) | 126 | CA (QD) | 67 | 1b (week 4, week 8) | 1b (week 4): 50.2% versus 31.2% (P<0.001) |
| | | | | | 3 (week 8) | 1b (week 8): 58.8% versus 40.8% (P<0.001) |
| | | | | | 4 (week 4, week 8) | 3 (week 8): 35.8% versus 17.7% (P=0.003) |
| Kaufmann 2002 | 0-4 CBD (QD) | 490 | CA (QD) | 480 | 1b (week 4) | 1b (week 1): 39.2% versus 23.4% (P<0.001) |
| | | | | | 3 (week 8) | 1a (week 1): 36.8±15.2% versus 26.5±14.5% (P<0.01) |
| | | | | | 4 (week 4) | 1a (week 2): 41.5±18.2% versus 33.7±16.9% (P<0.01) |
| | | | | | 4 (week 4) | 1a (week 4): 60.4±18.6% versus 50±19.4% (P<0.01) |
| | | | | | 4 (week 4) | 2 (week 1): 3.81±3.27 versus 5.47±3.47 (P<0.001) |
| | | | | | 4 (week 4) | 2 (week 4): 4.07±3.33 (P<0.001) |
| | | | | | 4 (week 4) | 2 (week 2): 3.81±3.27 versus 5.47±3.47 (P<0.001) |
| Saraceno 2007 | 0-4 CBD (QD) | 75 | CA (BID) | 75 | 2 (week 1, week 2, week 4) | 1a (week 1): 36.8±15.2% versus 26.5±14.5% (P<0.01) |
| | | | | | 2 (week 2) | 1a (week 2): 57±13.8% versus 44.8±16.9% (P<0.01) |
| | | | | | 2 (week 4) | 1a (week 4): 78±17.3% versus 62±18.6% (P<0.01) |
| | | | | | 2 (week 4) | 2 (week 1): 3.81±3.27 versus 5.47±3.47 (P<0.001) |
| | | | | | 2 (week 4) | 2 (week 2): 4.07±3.33 (P<0.001) |
| Kragballe 2004 | 0-8 CBD (QD) | 322 | CA (BID) | 327 | 1b (week 1, week 2, week 4, week 5) | 1b (week 1, week 2, week 4): T higher than C (P<0.05) |
| | | | | | 1b (week 4) | 1b (week 1): 45.5% versus 33.6% (P<0.001) |
| | | | | | 1b (week 4) | 1b (week 2): 68.6% versus 58.8% (P<0.001) |
| | | | | | 1b (week 4) | 1b (week 4): 63.3% versus 50.7% (P<0.033) |
| Guenther 2002 | 0-4 CBD (QD) | 150 | CA (BID) | 227 | 1b (week 1, week 4) | 1b (week 1): 45.5% versus 33.6% (P<0.001) |
| | | | | | 3 (week 4) | 1b (week 2): 68.6% versus 58.8% (P<0.001) |
| | | | | | 3 (week 4) | 1b (week 4): 63.3% versus 50.7% (P<0.033) |
| CBD (BID) versus CA (BID) |
| Papp 2003 | 0-4 CBD (BID) | 301 | CA (BID) | 308 | 1b (week 1, week 4) | 1b (week 1): 48.1% versus 28.4% (P=0.001) |
| | | | | | 1b (week 4) | 1b (week 2): 73.2% versus 48.8% (P<0.001) |
| | | | | | 1b (week 4) | 4 (week 4): 76.1% versus 33.4% (P<0.001) |
| Douglas 2002 | 0-4 CBD (BID) | 372 | CA (BID) | 369 | 1b (week 1, week 4) | 1b (week 1): 47.4% versus 31% (P<0.001) |
| | | | | | 1b (week 4) | 1b (week 4): 74.4% versus 55.3% (P<0.001) |
| | | | | | 1b (week 4) | 4 (week 4): 68% versus 38.9% (P<0.001) |
| CBD versus BE |
| CBD (QD) versus BE (QD) |
| Menter 2013 | 0-8 CBD (QD) | 482 | BE (QD) | 479 | 1b (week 4, week 8) | 1b (week 4): 46.4% versus 42.7% (P=0.038) |
| | | | | | 3 (week 4, week 8) | 1b (week 8): 55.8% versus 48.6% (P<0.001) |
| | | | | | 3 (week 4, week 8) | 3 (week 4): 23.1% versus 18.1% (P=0.07) |
| | | | | | 3 (week 4, week 8) | 3 (week 8): 40.8% versus 34.9% (P=0.004) |
| | | | | | 3 (week 4, week 8) | 4 (week 4): 13.3% versus 12.5% (P=0.82) |
| | | | | | 3 (week 4, week 8) | 4 (week 4): 29% versus 21.5% (P=0.008) |

Contd...
by investigator assessment. They showed a higher proportion of improvement in the calcipotriol/betamethasone dipropionate group (about 15% at week 4 and 30% at week 8) compared to that seen in the calcipotriol group (Week 4, $P = 0.019$, $P = 0.003$; Week 8, $P = 0.002$, $P = 0.009$).\[^{13,19}\]

**Comparison of calcipotriol/betamethasone dipropionate with betamethasone** (Table 2)

We identified five trials for this comparison, involving a total of 3471 participants.\[^{12,13,16,19,20}\] The frequency of application was once daily calcipotriol/betamethasone dipropionate versus once daily betamethasone in three studies, and twice daily calcipotriol/betamethasone dipropionate versus twice daily betamethasone in two studies.\[^{12,13,16,19,20}\]

Three studies treated the patients for four weeks.\[^{12,16,20}\] The evaluation of percentage reduction of PASI score showed a higher reduction in the calcipotriol/betamethasone dipropionate group compared to that in the betamethasone group ($P < 0.001$). A once daily application showed nearly 40% reduction and the twice daily application showed a reduction of around 50% at week 1. There was a reduction of 70% at week 4 with both once daily and twice daily applications. The studies also showed a higher proportion of “marked improvement or clearance” by investigator assessment in the calcipotriol/betamethasone dipropionate group (once daily being 60%, and twice daily being 70%) compared to that seen in the betamethasone group ($P < 0.001$) at week 4.

Two studies treated the patients for eight weeks and evaluated the percentage reduction of the PASI score.\[^{13,19}\] There was a higher reduction of the PASI score in the calcipotriol/betamethasone dipropionate group (about 50% at week 4) compared to that seen in the betamethasone group ($P = 0.037$ and $P = 0.038$). However, the results of PASI score reduction was not consistent at week 8. Although one study showed better efficacy in the calcipotriol/betamethasone dipropionate group versus the betamethasone group ($P < 0.001$), the other study showed no significant difference ($P = 0.17$). These two studies compared the rate of patients who achieved PASI 75 score. One study showed no significant difference between groups at Week 4 ($P = 0.07$). More patients achieved a PASI 75 score in the calcipotriol/betamethasone dipropionate group when compared to the betamethasone group at Week 8 ($P = 0.004$). However, another trial did not show such a difference at week 8 ($P = 0.18$). These two studies also evaluated the proportion of “marked improvement or clearance” by investigator assessment.

---

Table 2: Contd...

| Source             | Treatment period (week) | Treatment group | Control group | Evaluation time of outcome measurement | Efficacy (T vs. C) |
|--------------------|------------------------|----------------|--------------|----------------------------------------|-------------------|
| Fleming 2010       | 0-8                    | CBD (QD)       | BE (QD)      | 1b (week 4, week 8) 63.3% versus 73.5% ($P < 0.001$) | 1b (week 4) 50.2% versus 40.8% ($P = 0.037$) |
| Kaufmann 2002      | 0-4                    | CBD (QD)       | BE (QD)      | 1b (week 1) 47.4% versus 39.8% ($P < 0.001$) | 1b (week 1) 48.1% versus 41.4% ($P < 0.001$) |
| Douglas 2002       | 0-4                    | CBD (BID)      | BE (BID)     | 1b (week 1) 48.1% versus 41.4% ($P < 0.001$) | 1b (week 4) 73.2% versus 63.1% ($P < 0.001$) |
| Guenther 2002      | 0-4                    | CBD (QD)       | CBD (BID)    | 1b (week 1) 48.1% versus 41.4% ($P < 0.001$) | 1b (week 4) 50.2% versus 40.8% ($P = 0.037$) |

1a: Percentage reduction of PASI (mean±SD%), 1b: Percentage reduction of PASI (mean value%), 2: PASI score (mean±SD), 3: The mean number of patients who achieved PASI 75, 4: The proportions of “marked improvement or clearance” by the investigator assessment (%).CBD: Calcipotriol/betamethasone dipropionate, CA: Calcipotriol, BE: Betamethasone, QD: Once daily, BID: Twice daily, SD: Standard deviation, PASI: Psoriasis Area and Severity Index.
A higher proportion of improvement was seen in the calcipotriol/betamethasone dipropionate group compared to that seen in the betamethasone group at week 8 (\(P = 0.03\) and \(P = 0.008\)). Improved results were seen earlier at week 4 in one study.[13]

**Comparison of calcipotriol/betamethasone dipropionate once daily with calcipotriol/betamethasone dipropionate twice daily (Table 2)**

A four week trial was carried out for this comparison, with a total of 384 participants.[14] The study evaluated the percentage reduction of the PASI score at week 1 and week 4, and the proportion of “marked improvement or clearance” by investigator assessment at week 4. No statistically significant differences regarding any outcomes were seen between the two treatment protocols at any time point (\(P = 0.3\) and \(P = 0.052\)).

**Adverse effects**

The incidence of adverse effects ranged from 0% to 42.5% with once daily calcipotriol/betamethasone dipropionate, 5.3–38.3% with calcipotriol monotherapy, 3.1–48.2% with betamethasone monotherapy and 26.8–29.6% with twice daily calcipotriol/betamethasone dipropionate. Lesional and perilesional cutaneous adverse drug reactions were recorded meticulously. The most common adverse effect noted in all groups was pruritus. Other adverse effects included pain, folliculitis, rash, pustules, dermatitis, exfoliation, erythema, aggravation of psoriasis, skin irritation, telangiectasia, etc. The proportion of patients reporting cutaneous adverse effects to calcipotriol/betamethasone dipropionate was similar across once daily (0–10%) and twice daily (8–10%) applications. The incidence of cutaneous adverse effects ranged from 11-20% with calcipotriol monotherapy, and 0–9% with betamethasone monotherapy. The proportion of patients reporting adverse effects to calcipotriol/betamethasone dipropionate was significantly less than those only on calcipotriol. Other adverse effects included pain, folliculitis, rash, pustules, dermatitis, exfoliation, erythema, aggravation of psoriasis, skin irritation, telangiectasia, etc. The proportion of patients reporting cutaneous adverse effects to calcipotriol/betamethasone dipropionate was similar across once daily (0–10%) and twice daily (8–10%) applications. The incidence of cutaneous adverse effects ranged from 11-20% with calcipotriol monotherapy, and 0–9% with betamethasone monotherapy. The proportion of patients reporting adverse effects to calcipotriol/betamethasone dipropionate was significantly less than those only on calcipotriol. The main reasons for withdrawal from the treatment protocol included unacceptable adverse effects, unacceptable treatment efficacy, poor compliance, patient being lost to follow-up or complete resolution of lesions. The percentage of patients who withdrew from treatment due to adverse effects was about 1% in the once-daily calcipotriol/betamethasone dipropionate recipients, 1–10% in calcipotriol recipients, 1–6% in betamethasone recipients and 7.5% in the twice-daily calcipotriol/betamethasone dipropionate recipients.

The adverse effects usually resolved in a few weeks. The adverse effects are listed in Table 3.

**DISCUSSION**

We found several systematic reviews on topical calcipotriol/betamethasone dipropionate for the treatment of psoriasis. The current systematic review is conducted from various points of view. As calcipotriol/betamethasone dipropionate gel and ointment showed similar efficacies in previous studies, we included both formulations in our review.[10,11] This is the main difference compared to previous systematic reviews.[22-24] Our study also paid close attention to the fixed compound formulation on body lesions, and not scalp lesions alone.[22-25] A previous systematic review included both randomized controlled trials and non-randomized controlled trials.[24] As randomized controlled trials are considered to have a higher level of evidence, our review only included those studies. We included trials which had a duration of treatment ranging from four to eight weeks. Trials with a long term treatment duration of at least 24 weeks did not meet our inclusion criteria.[22,24-26] Our review focused on the comparison of calcipotriol/betamethasone dipropionate with calcipotriol or betamethasone and was an update to the previous systematic reviews which included studies up to 2012.[3,25-28] According to the Cochrane library, a systematic review should be updated within 3 years. We believe that our systematic review will provide valuable and direct information about calcipotriol/betamethasone dipropionate in the treatment of psoriasis.

To assess the methodological quality, we used the criteria recommended by the Cochrane Collaboration Handbook. Of the ten studies, 80% adequately described the sequence generation and 60% described the allocation concealment so the selection bias was generally controlled. About 50% of studies performed double blinding of participants which indicates a moderate risk of performance bias. The risk of detection bias was moderately controlled as 30% of studies performed blinding of outcome assessment. Over 90% studies addressed incomplete outcome data and all studies reported the selected outcome. So, the attrition bias and reporting bias were well controlled. The overall methodological quality of included studies was moderate to high.

Our systematic review demonstrated that treatment with the two-compound formulation of calcipotriol/
betamethasone dipropionate was more effective than either agent used alone. In the patients who were randomized to the calcipotriol/betamethasone dipropionate group, the percentage reduction of the PASI score was 40–48% at week 1, 50–74% at week 4 and remained at 55–73% at week 8. A higher reduction in the PASI score was observed after 1 week of treatment demonstrating the rapid onset of action of this compound. The improvement increased with continued application of the combination for four to eight weeks. The percentage of patients who showed marked improvement or clearance within 4 weeks of treatment, the percentage reduction of PASI score at week 1 and week 4 was not statistically or clinically significant. The proportion of “marked improvement or clearance” by investigator assessment at week 4 showed the same findings. 

This result provides a useful reference for calcipotriol/betamethasone dipropionate application as once daily usage enables higher compliance and is economical too.

The adverse effect profile of calcipotriol/betamethasone dipropionate was similar across included studies with a comparable percentage of patients reporting cutaneous adverse reactions during treatment. The calcipotriol/betamethasone dipropionate combination was found to be safer than calcipotriol. No statistically significant differences existed between calcipotriol/betamethasone dipropionate and betamethasone, or once-daily calcipotriol/betamethasone dipropionate and twice-daily calcipotriol/betamethasone dipropionate were compared after four weeks of treatment, the percentage reduction of PASI score at week 1 and week 4

| Source          | Interventions         | Total number of participants | Number of patients | Number of patients who withdrew due to adverse effects | Lesional/perilesional adverse effects |
|-----------------|-----------------------|------------------------------|--------------------|--------------------------------------------------------|---------------------------------------|
| Mellyanawati 2014 | CBD (QD) 30 0; CA (BID) 30 4 (13.3) | 0; 4 (13.3)                | 0; 4 (13.3)        | 0; 4 (13.3)                                            | 0; 4 (13.3)                           |
| Menter 2013     | CBD (QD) 482 5.0; CA (QD) 96 5.3; BE (QD) 479 3.1 | 3 (0.6); 4 (4.2)          | 3 (0.6); 1 (1.1)  | 0; 0; 0                                                | 3 (0.6); 1 (1.1); 0; 0; 0            |
| Fleming 2010    | CBD (QD) 162 42.5; CA (QD) 79 35.4; BE (QD) 83 48.2 | 0; 8 (10.1)               | 0; 7 (8.4)        | 0; 7 (8.4)                                             | 0; 7 (8.4)                            |
| Huang 2009      | CBD (QD) 160 25 (15.6); CA (BID) 160 33 (20.6) | 0; 1                   | 0; 1             | 0; 1                                                  | 0; 1                                  |
| Saraceno 2007   | CBD (QD) 75 7; CA (BID) 75 8 | 1; 5                     | 1; 5             | 1; 5                                                  | 1; 5                                  |
| Kragballe 2004  | CBD (QD) 322 -; CA (BID) 327 - | -; -                  | -; -             | -; -                                                  | -; -                                  |
| Papp 2003       | CBD (BID) 304 90 (29.6); CA (BID) 308 118 (38.3); BE (BID) 313 90 (28.8) | 16 (5); 27 (9); 17 (5) | 30 (9.9); 53 (17.2); 27 (8.6) | 9.9; 19.8; 4.7 | 9.9; 19.8; 4.7 |
| Douglas 2002    | CBD (BID) 372 99 (26.8); CA (BID) 369 130 (35.5); BE (BID) 365 117 (32.1) | 7.5; 10; 5.8 | 8.1; 12; 4.7 | 8.1; 12; 4.7 | 8.1; 12; 4.7 |
| Guenther 2002   | CBD (QD) 151; CBD (BID) 235 | 0 118 (24.3); 3 (0.6); 5 (1.1) | 0 9.9; 29 (6); 23 (4.9) | 0 118 (24.3); 3 (0.6); 5 (1.1) | 0 9.9; 29 (6); 23 (4.9) |
| Kaufmann 2002   | CBD (QD) 490; CA (QD) 480; BE (QD) 476 | 118 (24.3); 157 (33.1); 117 (24.7) | 3 (0.6); 15 (3.1); 5 (1.1) | 29 (6); 54 (11.4); 23 (4.9) | 29 (6); 54 (11.4); 23 (4.9) |

CBD: Calcipotriol/betamethasone dipropionate, CA: Calcipotriol, BE: Betamethasone, QD: Once daily, BID: Twice daily

When once-daily calcipotriol/betamethasone dipropionate and twice-daily calcipotriol/betamethasone dipropionate were compared after four weeks of treatment, the percentage reduction of PASI score at week 1 and week 4 was not statistically or clinically significant. The proportion of “marked improvement or clearance” by investigator assessment at week 4 showed the same findings. This result provides a useful reference for calcipotriol/betamethasone dipropionate application as once daily usage enables higher compliance and is economical too.
In a 52-week long-term study, treatment with calcipotriol/betamethasone dipropionate appeared to be safe and was well tolerated when used on its own or alternating every four weeks with calcipotriol.[30] Another six-month study showed high satisfaction and desire for repeated use of calcipotriol/betamethasone dipropionate in psoriasis vulgaris patients.[31] These results indicate a good safety profile of calcipotriol/betamethasone dipropionate.

CONCLUSION

Topical application of the two-compound product calcipotriol/betamethasone dipropionate provides good results for psoriasis vulgaris with only mild adverse effects. The optimal frequency of application is once daily. This combination is superior to either calcipotriol or betamethasone monotherapy when used for four to eight weeks, however longer durations of treatment are not recommended. We found that the studies included in this review were diverse and had limitations. Inconsistent treatment protocols, various outcome measurements, relatively short treatment duration and lack of long-term follow-up data were a few notable limitations. Randomized controlled trials that address these issues are needed in future studies.

Acknowledgement

The study was supported by skin disease research fund of China Society of Integrated Traditional Chinese and Western Medicine.

Financial support and sponsorship

Skin disease research fund of China Society of Integrated Traditional Chinese and Western Medicine.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbiditY (IMPACT) Project Team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
2. Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006;20:39-44.
3. Fonten C, Plesker GL. Calcipotriol/betamethasone dipropionate: A review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol 2004;5:463-78.
4. Cunliffe WJ, Berth-Jones J, Claudi A, Fairiss G, Goldin D, Gratton D, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26(5 Pt 1):736-43.
5. Kragballe K, Gjertsen BT, Hoop D, Karlsmark T, van de Kerkhof PC, Larkö O, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-6.
6. Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 1993;186:129-32.
7. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Møller S, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: Tolerability and efficacy. Br J Dermatol 1998;139:649-54.
8. van Rossum MM, van Erp PE, van de Kerkhof PC. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: A flow cytometric study. Dermatology 2001;203:148-52.
9. Saraceno R, Andreassi L, Ayala F, Bougnerro MR, Giannetti A, Lisi F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (DaivoneX) in the treatment of psoriasis vulgaris: A randomized, multicentre, clinical trial. J Dermatol Treat 2007;18:361-5.
10. Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4-and 12-week interim results from the PRO-long study. J Eur Acad Dermatol Venereol 2014;28:1723-31.
11. Queille-Roussel C, Hoffmann V, Ganslandt C, Hansen KK. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Clin Drug Investig 2012;32:613-9.
12. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5.
13. Fleming C, Ganslandt C, Guenther L, Johansson A, Buckley C, Simon JC, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: A randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010;20:465-71.
14. Guenther L, Van de Kerkhof PC, Smellman E, Kragballe K, Chu AC, Tegner E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23.
15. Huang L, Ma L, Huang Q, Yang YP, Zeng ZZ, Zhu XJ, et al. Calcipotriol betamemason ointment in the treatment of psoriasis vulgaris: A randomized, double-blind, active-controlled, parallel group study. Chin J Dermatol 2009;42:691-4.
16. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93.
17. Kragballe K, Noerreldun KL, Lui H, Ortonne JP, Wozel G, Uurasm-K, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-73.
18. Melyanaawati C, Huang X, Wei B, Fang S, Huuung K, Chen AJ. Efficacy safety and quality of life of topical calcipotriol
betamethasone dipropionate in treatment of psoriasis vulgaris. Chongqing Medicine 2014;43:1651-6.
19. Menter A, Gold LS, Bukhalo M, Grekin S, Kempers S, Boyce BM, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: A randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol 2013;12:92-8.
20. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54.
21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomized trials. BMJ 2011;343:d5928.
22. Daudén E, Bewley A, Lambert J, Girolomoni G, Cambazard F, Reich K. Expert recommendations: The use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2014;28 Suppl 2:22-32.
23. Kragballe K, van de Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol 2014;28 Suppl 2:10-21.
24. Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaçi D, Reusch M, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice. J Dtsch Dermatol Ges 2014;12:667-82.
25. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013;3:CD005028.
26. Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses. Br J Dermatol 2013;168:954-67.
27. Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag 2008;4:341-8.
28. van de Kerkhof P, de Peuter R, Ryttov J, Jansen JP. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin 2011;27:225-38.
29. Langley RG, Gupta A, Papp K, Wexler D, Østerdal ML, Curcic D. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: A randomized, controlled clinical trial. Dermatology 2011;222:148-56.
30. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60.
31. Claréus BW, Houwing R, Sindrup JH, Wigchert S. The DESIRE study – Psoriasis patients’ satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. Eur J Dermatol 2009;19:581-5.